JacobJ.AdashekDO

PubMed

• 16 citations
  Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis.
  Justin Shaya, Shumei Kato, Jacob J Adashek, Hitendra Patel, Paul T Fanta
  NPJ Genomic Medicine. 2023-01-20
• 24 citations
  The paradox of cancer genes in non-malignant conditions: implications for precision medicine
  Jacob J. Adashek, Shumei Kato, Scott M. Lippman, Razelle Kurzrock
  Genome Medicine. 2020-02-17
• 15 citations
  Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer.
  Jacob J. Adashek, Yadis M Arroyo-Martinez, Arjun K. Menta, Razelle Kurzrock, Shumei Kato
  Frontiers in Oncology. 2020-08-04

Journal Articles

• Infectious Complications of Mucositis in Postchemotherapy Neutropenic Cancer Patients: Three Case Reports and a Review of the Literature  
  Shah N, Adashek JJ, Molinas NL, Ramsakal A, Greene JN, Infectious Diseases in Clinical Practice, 9/2019
• The role of metastasectomy in the treatment of metastatic renal cell carcinoma  
  Adashek JJ, Aydin AM, Kim P, Spiess PE, AME Medical Journal, 6/28/2019

Abstracts/Posters

• LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
  Adashek JJ, Kato S, Pabla S, Nesline M, Conroy JM, Subbiah V, DePietro P, Kurzrock R., 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, 6/5/2022
• Immunoregulatory Molecule Expression Patterns Before and After Immune Checkpoint Inhibition: A Pilot Study
  Adashek JJ, Welence T, Lee S, Mareboina M, Koga M, Koga T, Pabla S, Glenn S, Nesline M, Conroy J, DePietro P, Kato S, Kurzrock R, 2021 JCA-AACR Precision Cancer Medicine International Conference Virtual, 9/22/2021
• The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications
  Adashek JJ, Andreev-Drakhlin A, Roszik J, Desai AP, Subbiah V, 2021 American Association for Cancer Research (AACR), Virtual, 4/10/2021
• Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAF V600-mutant multiple non-melanoma cancers: A clinico-genomic study
  Adashek JJ, Desai AP, Menta AK, Roszik J, Subbiah V., 2021 American Association for Cancer Research (AACR), Virtual, 4/10/2021
• Immunotherapy trials lack a biomarker for inclusion: implications for drug development
  Adashek JJ, Goloubev A, Kato S, Kurzrock R, Society for Immunotherapy of Cancer (SITC) 2020, Virtual, 11/9/2020
• Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes
  Adashek JJ, Kato S, Gumas S, Lee S, Okamura R, Sicklick J, Kurzrock R, European Society of Medical Oncology (ESMO) Congress 2020, Virtual, 9/18/2020
• Outcomes of advanced renal cell carcinoma with sarcomatoid features post-cytoreductive nephrectomy in clear cell and non-clear cell disease
  Adashek JJ, Bilotta A, Chahoud J, Li J, Spiess PE, American Association for Cancer Research (AACR) 2020, Virtual, 6/22/2020
• T-cell receptor clonotyping and immune infiltrate quantification with whole transcriptome RNA-seq from FFPE
  Sedgewick AJ, Adashek JJ, Szeto CW, Vaske CJ, Spiess PE, Benz SC, American Association for Cancer Research (AACR) 2020, Virtual, 6/22/2020
• Validated differential expression of immunoregulatory molecules that coincide with targetable mutations may provide novel insights into strategic trial design for ther...
  Adashek JJ, Szeto CW, Veerapaneni S, Preble A, Reddy SK, Spiess PE, American Association for Cancer Research (AACR) 2020, Virtual, 6/22/2020
• Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.
  Adashek JJ, Kato S, Okamura R, Khalid N, Lee S, Nguyen VT, Sicklick JK, Kurzrock R, American Society of Clinical Oncology (ASCO) 2020, virtual, 5/25/2020
• Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
  Adashek JJ, Szeto C, Sanborn JZ, Reddy SK, Toor AA, Danielides S, Smith S, Grossman SR, Clevenger CV, Faber A, Ferreira-Gonzalez A, Boikos SA, American Society of Clinical Oncology (ASCO) 2020, virtual, 5/25/2020
• Gene Silencing: Another Mechanism of Resistance?
  Adashek JJ, Kato S, Parulkar R, Szeto CW, Sanborn JZ, Vaske CJ, Benz SC, Reddy SK, Kurzrock R, NCCN 2020 Annual Conference, virtual, 4/17/2020
• Real-world data validation for differential expression of immunoregulatory molecules and targetable cancer genes may provide therapeutic insights into agnostic-driven ...
  Adashek JJ, Szeto CW, Reddy SK, Spiess PE, ASCO-SITC, Orlando, FL, 2/8/2020
• 50 gene breast cancer (BC) RNA subtype classifier and colorectal cancer (CRC) CMS subtype classifier applied to 90 prostate cancer (PC) patients reveals distinct subty...
  Pal SK, Veerapaneni S, Obeid E, Szeto CW, Reddy SK, Nussenzveig R, Agarwal N, 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference, Boston, Massachusetts, 10/28/2019
• Differential expression of immunoregulatory molecules and highly-associated cancer genes may provide novel insights into strategic trial design for therapeutics
  Adashek, JJ, Szeto, CW, Reddy, SK, Spiess, PE, European Society of Medical Oncology (ESMO) Congress, Barcelona, Spain, 9/30/2019
• Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cance...
  Adashek JJ, Won H, Moreira D, Duttagupa P, Twardowski P, Jones JO, Kortylewski M, Pal SK, American Society of Clinical Oncology: Genitourinary Cancers (ASCO-GU) Symposium, San Francisco, California, 2/26/2019
• RNAseq in addition to next generation sequencing in advanced cancers reveals lack of transcriptomic expression of DNA mutations: Implications for resistance to targete...
  Adashek JJ, Kato S, Parulkar R, Szeto C, Reddy SK, Kurzrock R, American Society of Clinical Oncology: Genitourinary Cancers (ASCO-GU) Symposium, San Francisco, California, 2/26/2019
• Comparative effect of body-mass index on outcome with targeted therapy and immunotherapy in patients with metastatic renal cell carcinoma (mRCC)
  Dizman N, Bergerot PG, Bergerot CD, Philip EJ, Salgia M, Hsu J, Adashek J, Pal SK, European Society of Medical Oncology (ESMO) Congress, 10/1/2018
• Is there a role for immunotherapy (IO) and tyrosine kinase inhibitors (TKI) for older adults with metastatic renal cell carcinoma (mRCC)?
  Dizman N, Bergerot PG, Bergerot CD, Hsu J, Adashek J, Dale W, Pal SK, American Society of Clinical Oncology (ASCO), Chicago, Illinois, 6/1/2018
• Association between mutation variant allele fractions (mVAFs) and response to immunotherapy (IO) in metastatic renal cell carcinoma (mRCC)
  Dizman N, Bergerot PG, Bergerot CD, Hsu J, Adashek J, Salgia M, Pal SK, American Society of Clinical Oncology: Genitourinary Cancers (ASCO), Chicago, Illinois, 6/1/2018
• Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC)
  Adashek J, Pal SK, Chung VM, Tagawa ST, Picus J, Babiker HM, Gupta S, Wadlow RC, Poore J, Peterson C, Benaim E, American Society of Clinical Oncology (ASCO), Chicago, Illinois, 2018
• One Minute Genetics: Wise choices in high value care based on the ACMG recommendations in the Choosing Wisely® Campaign
  Kim A, Rueda de León E, Adashek J, Mehta A, Schimek J, Bodurtha J, 2016 ACMG Annual Clinical Genetics Meeting, Tampa, Florida, 3/8/2016
• Join now to see all